We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+3.67%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$450M
AUM Growth
-$279M
Cap. Flow
-$152M
Cap. Flow %
-33.77%
Top 10 Hldgs %
60.29%
Holding
78
New
9
Increased
12
Reduced
27
Closed
29
Avg Time Held Equity + Options
1 year
Top 10 Avg Time Held Equity + Options
0.3 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
1 year
Top 10 Avg Time Held Equity only
0.4 years
Top 20 Avg Time Held Equity only
0.8 years

Top Buys

Rank Stock Value
1
AMRN icon
Amarin Corp
AMRN
+$35.2M
2
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$25.3M
3
OSUR icon
OraSure Technologies
OSUR
+$12.9M
4
CTLT icon
CATALENT, INC.
CTLT
+$11.9M
5
AMRX icon
Amneal Pharmaceuticals
AMRX
+$7.57M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$34M
2
AZN icon
AstraZeneca
AZN
+$27.9M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$23.9M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$15.9M
5
MYOV
Myovant Sciences Ltd.
MYOV
+$15.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.16%
2 Communication Services 1.48%
3 Miscellaneous 1.32%
4 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$47.2M 10.49%
607,757
-346,981
-36% -$23.9M
2020 Q2
1 quarter
AMRN icon
2
Amarin Corp
AMRN
$240M
$44.9M 9.97%
532,673
+293,368
+123% +$35.2M
2018 Q1
10 quarters
TGTX icon
3
TG Therapeutics
TGTX
$8.25B
$27.4M 6.08%
1,023,330
-1,477,942
-59% -$34M
2018 Q1
10 quarters
ASND icon
4
Ascendis Pharma A/S
ASND
$14.8B
$24.8M 5.52%
161,004
-59,340
-27% -$8.53M
2017 Q4
11 quarters
UTHR icon
5
United Therapeutics
UTHR
$22.8B
$24.3M 5.41%
240,904
+8,228
+4% +$903K
2020 Q2
1 quarter
TEVA icon
6
Teva Pharmaceutical Industries Limited
TEVA
$48.4B
$21.6M 4.79%
+2,394,355
New +$25.3M
2020 Q3
0 quarters
FATE icon
7
Fate Therapeutics
FATE
$214M
$21.4M 4.75%
535,036
+3,778
+0.7% +$132K
2018 Q4
7 quarters
BHVN icon
8
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$20.9M 4.65%
321,581
-126,683
-28% -$8.3M
2020 Q1
2 quarters
DCPH icon
9
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$20.6M 4.59%
402,433
-16,219
-4% -$795K
2018 Q4
7 quarters
ENSG icon
10
The Ensign Group
ENSG
$10.3B
$18.2M 4.05%
318,863
-108,444
-25% -$5.6M
2017 Q4
11 quarters
HSKA
11
DELISTED
Heska Corp
HSKA
$15.7M 3.49%
158,772
-121,484
-43% -$12M
2019 Q1
6 quarters
ZGNX
12
DELISTED
Zogenix, Inc.
ZGNX
$15.5M 3.45%
865,241
-141,842
-14% -$3.48M
2017 Q4
11 quarters
CTLT icon
13
DELISTED
CATALENT, INC.
CTLT
$12M 2.67%
+140,329
New +$11.9M
2020 Q3
0 quarters
OSUR icon
14
OraSure Technologies
OSUR
$251M
$11.4M 2.54%
+940,412
New +$12.9M
2020 Q3
0 quarters
AMRX icon
15
Amneal Pharmaceuticals
AMRX
$6.65B
$10.3M 2.29%
2,656,208
+1,769,621
+200% +$7.57M
2020 Q2
1 quarter
LAB icon
16
Standard BioTools
LAB
$246M
$9.68M 2.15%
1,302,353
+834,430
+178% +$5.76M
2020 Q2
1 quarter
QGEN icon
17
Qiagen
QGEN
$9.52B
$8.75M 1.94%
157,936
+80,166
+103% +$4.16M
2020 Q2
1 quarter
TARO icon
18
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$7.78M 1.73%
141,889
+36,720
+35% +$2.29M
2019 Q4
3 quarters
DHR icon
19
Danaher
DHR
$161B
$6.76M 1.5%
35,374
-86,289
-71% -$15.3M
2018 Q3
8 quarters
MODN icon
20
DELISTED
MODEL N, INC.
MODN
$6.67M 1.48%
188,967
-151,797
-45% -$5.73M
2019 Q3
4 quarters
HCA icon
21
HCA Healthcare
HCA
$98.6B
$6.53M 1.45%
52,400
+22,000
+72% +$2.72M
2020 Q1
2 quarters
AUPH icon
22
Aurinia Pharmaceuticals
AUPH
$2.2B
$6.42M 1.43%
435,995
-112,330
-20% -$1.63M
2020 Q2
1 quarter
AMRN icon
23
CALL
Amarin Corp
AMRN
$240M
$5.32M 1.18%
63,205
+9,190
+17% +$1.1M
2019 Q3
4 quarters
MNTA
24
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$5.17M 1.15%
98,501
-25,837
-21% -$1.07M
2020 Q1
2 quarters
VTRS icon
25
Viatris
VTRS
$21.3B
$4.82M 1.07%
+324,951
New +$5.19M
2020 Q3
0 quarters
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q3 2020 Portfolio in Review

As of Q3 2020, Eversept Partners held 78 positions worth $450M, down 38% from $729M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Eversept Partners withdrew a net $152M in Q3 2020, closing 29 positions and reducing 27 holdings. Its most notable exit was Myovant Sciences Ltd., an estimated $15.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 81% a quarter earlier, followed by Communication Services and Miscellaneous.

Against the trend, Eversept Partners opened a new position in Teva Pharmaceutical Industries Limited worth $21.6M.

  • Eversept Partners's largest Q3 2020 buy was Teva Pharmaceutical Industries Limited: 2,394,355 shares worth $21.6M.
  • Eversept Partners added most to Amarin Corp in Q3 2020, an estimated $35.2M increase.
  • Eversept Partners's biggest Q3 2020 reduction was TG Therapeutics, cutting an estimated $34M.
  • Eversept Partners fully exited Myovant Sciences Ltd. in Q3 2020, selling an estimated $15.7M.
  • Eversept Partners's ten largest holdings make up 60% of its $450M portfolio in Q3 2020.
  • Eversept Partners opened 9 new positions and closed 29 in Q3 2020.
  • Eversept Partners's portfolio value fell 38% quarter-over-quarter to $450M.

Based on Eversept Partners's 13F filing for Q3 2020, filed 12 Nov 2020.